121 related articles for article (PubMed ID: 37078422)
1. CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs.
Chiloiro S; Giampietro A; Gessi M; Lauretti L; Mattogno PP; Cerroni L; Carlino A; De Alessandris QG; Olivi A; Rindi G; Pontecorvi A; De Marinis L; Doglietto F; Bianchi A
J Neuroendocrinol; 2023 Apr; 35(4):e13263. PubMed ID: 37078422
[TBL] [Abstract][Full Text] [Related]
2. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours.
Iacovazzo D; Chiloiro S; Carlsen E; Bianchi A; Giampietro A; Tartaglione T; Bima C; Bracaccia ME; Lugli F; Lauretti L; Anile C; Gessi M; Colosimo C; Rindi G; Pontecorvi A; Korbonits M; De Marinis L
Endocrine; 2020 Mar; 67(3):651-658. PubMed ID: 31875303
[TBL] [Abstract][Full Text] [Related]
3. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
4. Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
Tomasik A; Stelmachowska-Banaś M; Maksymowicz M; Czajka-Oraniec I; Raczkiewicz D; Zieliński G; Kunicki J; Zgliczyński W
Front Endocrinol (Lausanne); 2022; 13():957301. PubMed ID: 36187106
[TBL] [Abstract][Full Text] [Related]
5. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
Durmuş ET; Atmaca A; Kefeli M; Çalışkan S; Mete O; Aslan K; Fidan M; Çolak R; Durmuş B
Growth Horm IGF Res; 2022 Dec; 67():101502. PubMed ID: 36115256
[TBL] [Abstract][Full Text] [Related]
6. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
[TBL] [Abstract][Full Text] [Related]
7. Infiltration by Intratumor and Stromal CD8 and CD68 in Cervical Cancer.
Dimitrova P; Vasileva-Slaveva M; Shivarov V; Hasan I; Yordanov A
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109686
[No Abstract] [Full Text] [Related]
8. Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas.
Lu JQ; Adam B; Jack AS; Lam A; Broad RW; Chik CL
Endocr Pathol; 2015 Sep; 26(3):263-72. PubMed ID: 26187094
[TBL] [Abstract][Full Text] [Related]
9. The Multibiomarker Acro-TIME Score Predicts fg-SRLs Response: Preliminary Results of a Retrospective Acromegaly Cohort.
Chiloiro S; Moroni R; Giampietro A; Angelini F; Gessi M; Lauretti L; Mattogno PP; Calandrelli R; Tartaglione T; Carlino A; Gaudino S; Olivi A; Rindi G; De Marinis L; Pontecorvi A; Doglietto F; Bianchi A
J Clin Endocrinol Metab; 2024 Apr; 109(5):1341-1350. PubMed ID: 37975821
[TBL] [Abstract][Full Text] [Related]
10. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.
Heck A; Emblem KE; Casar-Borota O; Bollerslev J; Ringstad G
Endocrine; 2016 May; 52(2):333-43. PubMed ID: 26475495
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
Clin Transl Oncol; 2021 Dec; 23(12):2513-2525. PubMed ID: 34089486
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer.
Lu J; Xu Y; Wu Y; Huang XY; Xie JW; Wang JB; Lin JX; Li P; Zheng CH; Huang AM; Huang CM
BMC Cancer; 2019 Sep; 19(1):920. PubMed ID: 31521128
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
15. Immune Microenvironment of Primary and Recurrent Craniopharyngiomas: A Study of the Differences and Clinical Significance.
Lin D; Wang Y; Zhou Z; Lin Z
World Neurosurg; 2019 Jul; 127():e212-e220. PubMed ID: 30880197
[TBL] [Abstract][Full Text] [Related]
16. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
Luque RM; Ibáñez-Costa A; Neto LV; Taboada GF; Hormaechea-Agulla D; Kasuki L; Venegas-Moreno E; Moreno-Carazo A; Gálvez MÁ; Soto-Moreno A; Kineman RD; Culler MD; Gahete MD; Gadelha MR; Castaño JP
Cancer Lett; 2015 Apr; 359(2):299-306. PubMed ID: 25637790
[TBL] [Abstract][Full Text] [Related]
17. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
18. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
Potorac I; Petrossians P; Daly AF; Alexopoulou O; Borot S; Sahnoun-Fathallah M; Castinetti F; Devuyst F; Jaffrain-Rea ML; Briet C; Luca F; Lapoirie M; Zoicas F; Simoneau I; Diallo AM; Muhammad A; Kelestimur F; Nazzari E; Centeno RG; Webb SM; Nunes ML; Hana V; Pascal-Vigneron V; Ilovayskaya I; Nasybullina F; Achir S; Ferone D; Neggers SJ; Delemer B; Petit JM; Schöfl C; Raverot G; Goichot B; Rodien P; Corvilain B; Brue T; Schillo F; Tshibanda L; Maiter D; Bonneville JF; Beckers A
Endocr Relat Cancer; 2016 Nov; 23(11):871-881. PubMed ID: 27649724
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of preoperative systemic inflammatory markers in oral squamous cell carcinoma, and correlations with the local immune tumor microenvironment.
Ruiz-Ranz M; Lequerica-Fernández P; Rodríguez-Santamarta T; Suárez-Sánchez FJ; López-Pintor RM; García-Pedrero JM; de Vicente JC
Front Immunol; 2022; 13():941351. PubMed ID: 35958590
[TBL] [Abstract][Full Text] [Related]
20. Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly.
Chiloiro S; Costa D; Lauretta R; Mercuri V; Sbardella E; Samperi I; Appetecchia M; Bianchi A; Giampietro A; Gargiulo P; Isidori AM; Poggi M; Pontecorvi A; De Marinis L
Endocrine; 2022 Nov; 78(2):343-353. PubMed ID: 35986839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]